Kenvue (KVUE) Q3 Earnings Surpass Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.
Kenvue misses quarterly sales estimates on sluggish skincare sales
Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from activist hedge fund Starboard Value.
Stay Ahead of the Game With Kenvue (KVUE) Q3 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Kenvue (KVUE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
This Big New Development Could Be Bullish for Kenvue Stock
Can tinkering around the edges actually make this stock more attractive?
Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.
Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
An activist investor is taking a stake in Kenvue stock.
How activist Starboard may help boost value in Kenvue's skin and beauty business
Starboard Value and Kenvue seem to be aligned, and the conditions might be right for value creation.
Is Kenvue Stock a Buy Now?
The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.
Starboard says Kenvue's skin health segment is weighing on performance
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.
3-Stock Lunch: Kenvue, UPS & Disney
Sylvia Jablonski, Defiance ETF co-founder, joins 'Power Lunch' to discuss stock plays for three stocks.
Investor Hoping To "Band-Aid" KVUE Stock Price
The Wall Street Journal reported that Starboard Value has taken a "sizeable" stake in Kenvue (KVUE) with hopes of matching the company's stock price to competitors. Despite having Tylenol and Band-Aid as part of its brand portfolio, George Tsilis looks at the headwinds facing Kenvue's growth.
Kenvue gains on reports activist investor Starboard Value has taken ‘sizeable' stake
Kenvue Inc (NYSE:KVUE) shares moved more than 6% higher on reports activist investor Starboard Value has taken a stake in the consumer goods company and is eyeing changes. A person familiar with the matter told the Wall Street Journal that Starboard's stake in the Tylenol-maker is “sizeable.
